Molecular Partners AG
Index- P/E1.88 EPS (ttm)3.69 Insider Own- Shs Outstand32.51M Perf Week4.03%
Market Cap241.65M Forward P/E- EPS next Y-2.00 Insider Trans- Shs Float19.16M Perf Month12.99%
Income123.30M PEG- EPS next Q- Inst Own3.20% Short Float / Ratio0.06% / 1.31 Perf Quarter18.77%
Sales198.30M P/S1.22 EPS this Y18.10% Inst Trans2.68% Short Interest0.01M Perf Half Y-5.05%
Book/sh8.12 P/B0.86 EPS next Y-154.10% ROA108.30% Target Price14.67 Perf Year-39.00%
Cash/sh8.08 P/C0.86 EPS next 5Y- ROE129.80% 52W Range5.50 - 32.04 Perf YTD-63.71%
Dividend- P/FCF0.78 EPS past 5Y- ROI-56.00% 52W High-78.28% Beta-
Dividend %- Quick Ratio14.40 Sales past 5Y- Gross Margin- 52W Low26.55% ATR0.31
Employees164 Current Ratio14.40 Sales Q/Q-31.40% Oper. Margin- RSI (14)58.44 Volatility4.57% 3.40%
OptionableNo Debt/Eq0.02 EPS Q/Q-7.40% Profit Margin- Rel Volume2.44 Prev Close7.08
ShortableYes LT Debt/Eq0.02 EarningsAug 25 AMC Payout0.00% Avg Volume9.46K Price6.96
Recom2.70 SMA206.42% SMA508.77% SMA200-33.25% Volume23,084 Change-1.69%
Aug-30-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-29-22Downgrade SVB Leerink Outperform → Mkt Perform $30 → $8
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Dec-01-22 11:46PM
Nov-10-22 01:00AM
Nov-04-22 09:39AM
Nov-03-22 12:30PM
Nov-02-22 12:30PM
04:00PM Loading…
Oct-27-22 04:00PM
Aug-25-22 04:30PM
Aug-18-22 01:00AM
Jul-21-22 11:30AM
Jun-10-22 01:00AM
May-12-22 04:05PM
May-11-22 01:00AM
May-03-22 12:00PM
Apr-27-22 08:02AM
06:01AM Loading…
Apr-26-22 04:05PM
Apr-23-22 01:00AM
Apr-13-22 12:00PM
Mar-24-22 02:00AM
Mar-17-22 01:00AM
Mar-15-22 04:30PM
Feb-25-22 04:30PM
Feb-11-22 04:10PM
Feb-10-22 07:13AM
Jan-28-22 05:57AM
02:28AM Loading…
Jan-23-22 02:28AM
Jan-18-22 01:00AM
Jan-13-22 05:00PM
Jan-12-22 10:13AM
Jan-11-22 11:37AM
Jan-10-22 06:51PM
Jan-06-22 10:00AM
Jan-05-22 04:05PM
Dec-15-21 01:00AM
Dec-14-21 12:16PM
Dec-12-21 04:00PM
Dec-09-21 01:00AM
Dec-06-21 01:00AM
Dec-03-21 01:00AM
Nov-30-21 12:48PM
Nov-24-21 01:00AM
Nov-16-21 06:49AM
Nov-04-21 02:00AM
Oct-28-21 01:00AM
Oct-20-21 01:00AM
Sep-03-21 04:05PM
Aug-26-21 01:00AM
Aug-09-21 01:00AM
Jul-13-21 06:55AM
Jul-08-21 09:04AM
Jun-15-21 10:00PM
Jun-13-21 04:00PM
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.